Best Cardiac and Vascular Disorders Companies in England, United Kingdom

Developer of small molecule inhibitors targeting specific disease associated enzymes. These therapeutic candidates focus on the regulation of cellular quality control processes to address neurodegenerative conditions, heart disease, kidney disease, and fibrosis. The research centers on the modulation of protein degradation pathways to influence disease progression.

Funding rounds

• Oct 2025Series D$13.3M
• Jul 2024Grant (prize money)$5.2M
• Mar 2024Series D$32.2M
• Jan 2021Series C$3.7M

Founders & team

Keith MenearCo-FounderAnker LundemoseCEO

Investors

Innovate UK, Imperial Innovations, Woodford Investment Management, Roche, Pfizer Venture Investments, Sofinnova Partners

Developer of a method to profile the biology of coronary artery. It is building cohorts to endotype the disease for the first time. The approach enables the identification of new disease-specific drug targets. This paves the way for precision medicine for patients with coronary artery disease.

Developer of oral and injectable peptide therapies for metabolic diseases. Research focuses on creating rationally engineered peptides to address obesity and related cardiometabolic conditions. The pipeline includes oral formulations of GLP-1 analogs and amylin-based candidates designed for once-weekly administration. These therapeutic programs utilize proprietary absorption enhancers to support delivery and manufacturing. The portfolio encompasses both monotherapies and combination treatments aimed at managing weight and metabolic health through various biological mechanisms.

Funding rounds

• Jan 2025Series A$411M

Founders & team

Khurem FarooqCo-Founder & CEO

Investors

Forbion, General Atlantic, RA Capital Management, Orbimed, LAV Asset Management, LYFE Capital

Developer of smart devices for monitoring coronary artery disease and microvascular dysfunction. The company is involved in the development of optical-fiber based sensors that integrate into medical devices for monitoring cardiac helath. It has developed iKOs microcatheter device that uses nanomaterials and sensors that can be positioned into cardiovascular devices for detecting the heart conditions by using iKOR technology.

Funding rounds

• Nov 2025Series A$250K
• Mar 2024Series A$5.4M
• Sep 2019Series A$4.4M
• Sep 2019Grant (prize money)—

Founders & team

Ioannis PapakonstantinouCo-FounderRichard ColchesterCo-Founder

Investors

Parkwalk, UCL Technology Fund, Gov, AlbionVC, P4

InterVene is a medical device start-up company developing therapy for severe venous disease in the legs. This technology represents catheter-based, non-implantable approach, which allows physicians to create new vein valves for patients who are unable to efficiently pump blood out of their legs and back to their heart. Its catheter technology is based on a proved open-surgical predicate (Maleti Neovalve) that durably creates new valves out of the patient's native vein wall tissue. This minimally invasive approach allows for access to a new segment of the CVI market by transitioning that strategy of care away from costly, chronic, disease management to curative intervention

Funding rounds

• Oct 2024Series B$13M
• Mar 2023Series B$1.5M
• Jun 2019Series B$15M
• Jun 2017Series A$2.2M

Founders & team

Iden ShamsExecutive Director

Investors

3x5 Partners, RiverVest Venture Partners, Boston Scientific, Correlation Ventures, Treo Ventures, North Texas Angel Network

Tech stack

Animate.CssAstraBeaver BuilderCloudflareCloudflare Bot ManagementDocusign

Developer of antibodies against vascular diseases. It is developing isoform-specific, humanized IgG1-based antibodies using a combined bioinformatics-based platform against Vascular Endothelial Growth Factor A (VEGF-A).

Funding rounds

• Feb 2024Series A$9.5M
• Dec 2022Seed$1M

Founders & team

David BatesChief Scientific Officer and FounderJackie TurnbullCEO

Investors

Broadview Ventures, Midlands Engine Investment Fund, Mercia, SCVC, Nottingham Technology Ventures

Deltex Medical develops fluid management devices. CardioQ-ODM+ is a fluid management and cardiac output monitoring system to measure both flow and pressure. It is designed for intensive care and high risk surgical application. It brings together oesophageal doppler monitoring flow based technology with pulse pressure waveform system.

Developer of technology for cardiac disease risk assessment and analysis. The company provides tools for preventive screening, disease diagnosis, and intervention planning. It supports drug clinical trials and clinical research. The technology analyzes inflammation related to cardiac issues.

Funding rounds

• Apr 2023Series A$16.3M
• Mar 2021Series A—
• Mar 2021Grant (prize money)$639.7K
• Oct 2018Seed$2.6M

Founders & team

Stefan NeubauerCo-FounderKeith ChannonCo-FounderCharalambos AntoniadesFounder

Investors

Oxford Science Enterprises, Longwall Venture Partners, Oxford Investment Consultants, BGF, University of Oxford, Europa

Tech stack

Amazon SesAmazon Web ServicesAosBamboohrBootstrapCdnjs

GEN inCode is a developer of precision medicines by combining genetic and clinical data for cardiac disease monitoring. It provides solutions for the prevention and treatment of cardiovascular disease risk. The models are based on algorithms and machine learning which allows doctors to accurately measure and assess a patient's clinical and genetic risk.

Sky Medical Technology Limited does business as Firstkind Limited, and manufactures and distributes electro-simulation devices for the treatment of Deep vein thrombosis and other circulatory disorders. The company develops a self-adhesive strip, called Geko, that sits behind the knee and stimulates muscles in the calf and foot. Small electrical impulses gently stimulate the common peroneal nerve which in turn activates the muscle pumps of the lower leg that return blood towards the heart. In this way, neuromuscular stimulation in the lower limb emulates the process normally achieved by walking (up to 60%) but without the patient having to move or exert energy and without discomfort.

Funding rounds

• Feb 2020Series B$181K
• Mar 2019Series B$2.7M
• Mar 2018Series B$1.2M
• Mar 2017Series B$11.7M

Founders & team

Bernard RossCEO and Founder

Investors

Deepbridge Capital, Juno Capital, Bionow, Longbow Capital, Nissha, Barenco

Developer of cell-based therapeutic solutions for the treatment of multiple therapeutic conditions. The company has developed lead candidate REX-001 that is an autologous bone-marrow-derived cell suspension product that consists of a combination of progenitor cells and immune cells such as lymphocytes, monocytes & granulocytes. It is designed to address complex diseases such as plaque deposition, inflammation, ischemia, vessel degeneration, cardiac disorders, ulcer formation, and more. It provides targeted nanoparticles that are immunotherapies to stimulate the patient’s immune system to eliminate cancer cells. It has also developed a CELTIC program that involves in the treatment of hematological malignancies.

Funding rounds

• Jan 2021Series C$54.3M
• Jan 2018Grant (prize money)$1.9M

Founders & team

Vicente GonzalezCo-Founder

Investors

Innovate UK, Lilac Dawn Investments, Winstonb

NeoGraft Technologies is developing Angioshield, an intraoperative system that creates a micro-fibrous, polymer sleeve surrounding the outside surface of a harvested vein to mechanically reinforce it. The technology thus strengthens the grafted veins used in Coronary Artery Bypass Graft(CABG). As of now, the product is not approved for clinical use.